Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas
| العنوان: | Anti‑EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas |
|---|---|
| المؤلفون: | Junko Takei, Takuro Nakamura, Masato Sano, Tomokazu Ohishi, Hideki Hosono, Hiroyuki Harada, Yusuke Sayama, Mika K. Kaneko, Teizo Asano, Manabu Kawada, Miyuki Yanaka, Yukinari Kato |
| المصدر: | Oncology Reports |
| بيانات النشر: | Spandidos Publications, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, medicine.drug_class, Cell, Apoptosis, CHO Cells, Monoclonal antibody, Flow cytometry, Mice, 03 medical and health sciences, chemistry.chemical_compound, Antineoplastic Agents, Immunological, Cricetulus, 0302 clinical medicine, Cell Line, Tumor, medicine, Animals, Humans, antitumor activity, Cell adhesion, Antibody-dependent cell-mediated cytotoxicity, medicine.diagnostic_test, Squamous Cell Carcinoma of Head and Neck, Chemistry, Antibody-Dependent Cell Cytotoxicity, Antibodies, Monoclonal, Epithelial cell adhesion molecule, Articles, General Medicine, oral cancer, Cell cycle, Epithelial Cell Adhesion Molecule, Xenograft Model Antitumor Assays, stomatognathic diseases, 030104 developmental biology, medicine.anatomical_structure, Oncology, monoclonal antibody, Cell culture, EpCAM, 030220 oncology & carcinogenesis, Cancer research, Female, Mouth Neoplasms, ADCC, CDC |
| الوصف: | The epithelial cell adhesion molecule (EpCAM) is a calcium‑independent, homophilic, intercellular adhesion factor classified as a transmembrane glycoprotein. In addition to cell adhesion, EpCAM also contributes to cell signaling, differentiation, proliferation, and migration. EpCAM is an essential factor in the carcinogenesis of numerous human cancers. In the present study, we developed and validated an anti‑EpCAM monoclonal antibody (mAb), EpMab‑16 (IgG2a, kappa), by immunizing mice with EpCAM‑overexpressing CHO‑K1 cells. EpMab‑16 specifically reacted with endogenous EpCAM in oral squamous cell carcinoma (OSCC) cell lines in flow cytometry and Western blot analyses. It exhibited a plasma membrane‑like stain pattern in OSCC tissues upon immunohistochemical analysis. The KD for EpMab‑16 in SAS and HSC‑2 OSCC cells were assessed via flow cytometry at 1.1x10‑8 and 1.9x10‑8 M, respectively, suggesting moderate binding affinity of EpMab‑16 for EpCAM. We then assessed whether the EpMab‑16 induced antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC) against OSCC cell lines, and antitumor capacity in a murine xenograft model. In vitro experiments revealed strong ADCC and CDC inducement against OSCC cells treated with EpMab‑16. In vivo experiments on OSCC xenografts revealed that EpMab‑16 treatment significantly reduced tumor growth compared with the control mouse IgG. These data indicated that EpMab‑16 could be a promising treatment option for EpCAM‑expressing OSCCs. |
| تدمد: | 1791-2431 1021-335X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a253cee6c5fe8f2e86c556f182bac3c https://doi.org/10.3892/or.2020.7808 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4a253cee6c5fe8f2e86c556f182bac3c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17912431 1021335X |
|---|